Anti-aging glycopeptide (AAGP®)
See the science and potential of our patented AAGP® molecule
“The molecule works, and it does what it says it’s going to do. This could be as big as the introduction of Tylenol or Penicillin.”
– Dr. Asim Raja, podiatrist and ProtoKinetix investor
Changing lives through cell survival
Become part of the next great medical discovery. AAGP®, our proprietary anti-aging glycopeptide has incredible opportunities to improve health therapies for ophthalmology, dermatology, transplants and biomanufacturing. By protecting cells against inflammation, AAGP® could be the essential link to medical advancements that provide more hope to more patients.
AAGP® key benefits
Backed by research
Keeps cells alive
Protects against inflammation
Safe for humans
Cell survival is in our nature
Molecules must be less than 1,000 Daltons to pass through cell junctions into neighboring cells and less than 600 Daltons to diffuse through capillaries or cross the blood-brain barrier. AAGP® was invented to be a smaller, more stable synthetic version of AFGPs. They are just 580.96 Daltons and much less expensive to produce.
- 2002 Initial public offering
- 2003 First intellectual property (IP) filing
- 2005 Initial application for pipeline research
- 2010 Good Manufacturing Practice processing and toxicology study success
- 2014 IP second filing and Type 1 diabetes islet transplantation study
- 2016 Preclinical validation in Type 1 diabetes and peer reviewed papers
- 2016 IP third filing and induced pluripotent stem cells study for macular degeneration
- 2019 Preclinical validation in macular degeneration
- 2020 Investigational Drugs and Devices approval from the Food and Drug Administration for topical products
- 2020 Large-scale bioproduct validation
- 2020 First licensing agreement for topical products
- 2021 Published phase one clinical results for Type 1 diabetes
- 2021 Orphan disease status approval
- 2021 Initiate phase one clinical trial for macular degeneration
- 2022 Initiate phase two clinical trial for Type 1 diabetes
- 2022 Milestone partnership agreement for biological biosimilar production
- Molecular formula: C20H35CIF2N4O11
- Structure: Ala-Ala-Lys-F-C-F-Galactose
- Molecular mass: M = 580.96 g.mol-1
- Size: 580.96 Daltons
Solubility (at 25°C)
- Solubility in water: 650 g.L-1
- Soluble in water, methanol ethanol and DMSO
- Lightly lipid soluble
- White powder
- Highly hygroscopic
- Stable at a pH of 2 to 14
- Stable at temperatures of -196°C + 37°C
- No enzyme degradation from proteases or galactosidases
- Optimal concentration of 1 to10 mg/ml, depending on cell lines and stress tests
- Optimal pH of 5.3 to 7.3, depending on cell lines and stress tests
Mechanism of action
AAGP®’s ability to protect against inflammation-induced cell death in exposure to hydrogen peroxide, UVA and UVC suggests a role for AAGP® in the inflammation pathway. When exposed to an inflammatory mediator, interleukin ß (ILß), the presence of AAGP® reduced COX-2 expression threefold.
Inflammation plays a major role in many pathological conditions suggesting AAGP® may not just be usable in cell and organ storage but also in pharmacological treatments.
Since 2005, AAGP® has gone through international laboratory testing conducted by some of the top researchers in the world. See their scientific contributions.
We are moving cell survival forward by addressing the health conditions that affect our lives. See where we are today and where we are heading next.